[Antitumor effect of cis-diamminedichloroplatinum (II) against transplantable ovarian adenocarcinoma cells of the rat].
We studied on the antitumor effect of cis-diamminedichloroplatinum (II) (CDDP) with different dose schedules against a transplantable ovarian adenocarcinoma cell line of Sprague-Dawley rat. CDDP was administered intraperitoneally in the rats at doses of 2 to 4 mg/kg body weight every 3 weeks or one third of the doses every week. Administration of 2 mg/kg every 3 weeks seemed to be the most effective. In contrast to non-treated tumor tissues, in rats administered with CDDP thrombus formations were detected in many areas of the tumor tissues and obstruction of blood supply seemed to be a cause of cell damage. Severe nephro- and hepatotoxicities were observed after 4 courses of CDDP administration. Histologically vacuolated degeneration of cytoplasm and disappearance of nuclei were observed in renal proximal tubules.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000818:Animals; D002945:Cisplatin / Q000627:therapeutic use*; D005260:Female; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D051381:Rats; D011919:Rats, Inbred Strains
D002945:Cisplatin